TRIAL DETAIL
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma |
|||
NCT#: |
||||
Conditions: |
Solid Tumors |
|||
Status: |
Ongoing, but not recruiting |
|||
Phase: |
1 |
Start Date 11/01/2011 |
Age of Trial (yrs) 12.5 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
AKT inhibitor |
|||
Strategy: |
Block AKT |
|||
Trial Type: |
GIST not specified. GIST patient enrollment unknown. |
|||
Other Protocol IDs: |
ARQ 092-101 |
|||
Sponsor: |
ArQule |
|||
Patient Contact: |
ArQule, Inc
781-994-0300
ClinicalTrials@arqule.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
Purpose This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma. The study is designed to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to define a recommended Phase 2 dose of ARQ 092. |
|||
Trial Links |
Trial Results |
Drug Information |
| ArQule website |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1475 Northwest 12th Ave |
Miami |
FL |
33136 |
USA |
|
10460 N. 92nd St. |
Scottsdale |
AZ |
85258 |
USA |
|
1365C Clifton Road |
Atlanta |
GA |
30322 |
USA |
|
4319 Medical Dr. |
San Antonio |
TX |
78229 |
USA |
|
Lafayette |
IN |
47905 |
USA |
||
Atlanta |
GA |
30341 |
USA |